{"ticker": {"uuid": "0191e030-38e8-4a0d-9732-8b81d836b394", "symbol": "XNCR", "name": "Xencor Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus", "summary": "This article analyzes two Federal Circuit decisions, *Teva v. Eli Lilly* and *In re Xencor*, which provide guidance on patent method-of-use claims involving known compounds. The decisions highlight the importance of written description and enablement under 35 U.S.C. \u00a7 112, partic", "url": "https://www.foley.com/insights/publications/2026/07/pharmaceutical-method-of-use-claims-after-teva-v-eli-lilly-and-in-re-xencor-written-description-enablement-and-the-known-compound-genus/", "source_name": "Foley & Lardner LLP", "published_at": "2026-07-15T17:48:28", "published_display": "15 Jul 2026 17:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor: Bullish On Their Increasingly In-House Pipeline (NASDAQ:XNCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQTk5HdHhXOTVzQzdqQ2Q2VzdSLWhKMDUtSlV4MUVuNEFDUWZEcFlsUzh4WmE0ZHZQZzBLT2k2LVdlc3pHQ1V0TWJuN1hSRzdyc3NUTmhuTVo3VzNoVC1xVE51MHYzTzRSTEloYmFxM0UxcXljX2NjaVplTTFRQ2wya1J6UnFqQmdqemVLbEFEZTNPd1VDal9mMEMtQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T20:01:56+00:00", "published_display": "14 Jul 2026 20:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (NASDAQ:XNCR) Shares Down 6.6% - Should You Sell?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNTVltdGJ0SV90U0pybHlteU5kRTA5OTJrR0ZxVlhtY2ZqVUN4RFFvQnloMU4yZlVFS05FUGJLdWp1M3lma1Z0aWFCNWN6QVRDTDFIaU9aVTlGWmVsaFRLUk8tNTdERUpab2M1Z195VkdwRFl3S0wwNGNKWlJzSUJsYUwxYkNhYjd6dU5LVm5ScjdwU1ZBREl4M0lBWUxyM3k4SVByRg?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T18:19:19+00:00", "published_display": "13 Jul 2026 18:19", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of \"Moderate Buy\" from Analysts", "summary": "Xencor, Inc. (NASDAQ:XNCR) has received a consensus \"Moderate Buy\" rating from analysts, with ten firms covering the stock and an average 1-year price target of $24.25. Recent analyst actions have been mixed, including Truist lowering its target but maintaining a buy rating, and ", "url": "https://www.marketbeat.com/instant-alerts/xencor-inc-nasdaqxncr-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T07:11:54", "published_display": "13 Jul 2026 07:11", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) Rebounds Sharply, Is It Still A Bargain?", "summary": "Xencor (XNCR) has seen a sharp rebound in its share price recently, with 30-day and 90-day returns of 33.98% and 27.62% respectively, despite a longer-term decline. Analysts consider Xencor undervalued with a fair value of $28.50 compared to its current $15.85, driven by its modu", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xncr/xencor/news/xencor-xncr-rebounds-sharply-is-it-still-a-bargain", "source_name": "Simply Wall Street", "published_at": "2026-07-12T00:41:29", "published_display": "12 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(XNCR) Movement as an Input in Quant Signal Sets", "summary": "This article provides an in-depth quantitative analysis of Xencor Inc. (NASDAQ: XNCR) based on AI models from Stock Traders Daily. It highlights strong sentiment across all horizons, identifies a mid-channel oscillation pattern, and outlines specific trading strategies (Position,", "url": "https://news.stocktradersdaily.com/news_release/1/XNCR_Movement_as_an_Input_in_Quant_Signal_Sets_071026112002_1783740002.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T23:20:00", "published_display": "10 Jul 2026 23:20", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Xencor Inc For: 8 July By Investing.com", "summary": "This article from Investing.com reports the filing of a Form 4 for Xencor Inc, dated July 8th. The brief news item also mentions Xencor's stock, XNCR, experiencing a -2.13% change. The content primarily focuses on market data, unrelated news headlines, and advertising rather than", "url": "https://ng.investing.com/news/stock-market-news/form-4-xencor-inc-for-8-july-93CH-2592039", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T10:41:18", "published_display": "09 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) director granted RSUs and 20,604 stock options at $12.20", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNS0lRcGFSZkF4b3NUT19ueGJCbk1Oci1TbE5SdWlhY19HelJac1MyQXdJeXhyU0JwNGdkeEE1eGxac0d4dlBSQlhwalBtSkp2SGM3WXVwNFpWVmJiX0FSYm5RbDhNcUdJY3ZYZUQ1RDBlNFphbWlvNl8tLXFZSUkwZnQzbWR6bm4xLXdJVzRGdTdrNVlRYTRsRDhLYTZxMXRiSkczSUxFMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T22:53:49+00:00", "published_display": "08 Jul 2026 22:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (NASDAQ: XNCR) director receives new RSU and stock option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOd0FDZVA3Z1VSNXdjQ2ZPLW9icjE3SkRTajhXODZYWGJUMk44UEs1ZVI1SW04R1dseVM2VHFvcUV1T2FWT2o4SGR2Y3ZIemNENUFsOWc3Qm95V1RidFV1b1E5TmRneGM4d2hOOVdvRDU1RXNtR1d0YTJmQ3BqY21rUWZXN0NUVW10ekJCMG1DVm1UOExzSVhfbElYdmtVYjBMLUViYkhvYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T22:52:20+00:00", "published_display": "08 Jul 2026 22:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) director granted RSUs and stock options in equity award", "summary": "Xencor Inc. director Alan Bruce Montgomery received equity compensation, not open-market stock purchases, consisting of 10,302 restricted stock units (RSUs) and options for 20,604 shares. The RSUs will vest fully on the first anniversary of the grant date, while the stock options", "url": "https://www.stocktitan.net/sec-filings/XNCR/form-4-xencor-inc-insider-trading-activity-38aa42b7ba3a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T23:10:40", "published_display": "08 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) director Kurt Gustafson granted RSUs and stock options", "summary": "Xencor director Kurt A. Gustafson received 10,302 restricted stock units (RSUs) and options for 20,604 shares of Common Stock with an exercise price of $12.20. These equity awards, not open-market trades, are part of his compensation, with RSUs vesting on the first anniversary of", "url": "https://www.stocktitan.net/sec-filings/XNCR/form-4-xencor-inc-insider-trading-activity-1f92ecef9d95.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:55:27", "published_display": "08 Jul 2026 22:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Xencor Inc Insider Trading Activity", "summary": "Xencor Inc. director Barbara Klencke recently reported receiving equity compensation. This included 10,302 restricted stock units vesting a year from June 16, 2026, and options to purchase 20,604 shares at an exercise price of $12.20, vesting monthly over one year. Following thes", "url": "https://www.stocktitan.net/sec-filings/XNCR/form-4-xencor-inc-insider-trading-activity-8fb0259010bc.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:54:27", "published_display": "08 Jul 2026 22:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ellen Feigal at Xencor (XNCR) receives RSUs and options equity awards", "summary": "Xencor Inc. director Ellen Feigal was granted 10,302 restricted stock units (RSUs) and stock options for 20,604 shares. The RSUs will fully vest on June 16, 2027, one year from the grant date, while the stock options, with an exercise price of $12.20 per share, will vest in equal", "url": "https://www.stocktitan.net/sec-filings/XNCR/form-4-xencor-inc-insider-trading-activity-da620bd99669.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:35:30", "published_display": "08 Jul 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) awards RSUs and stock options to director Gorman", "summary": "Xencor Inc. (XNCR) director Kevin Charles Gorman was granted 10,302 restricted stock units (RSUs) and stock options for 20,604 shares on June 16, 2026, as part of his compensation. The RSUs will vest fully on the first anniversary of the grant date, while the stock options, with ", "url": "https://www.stocktitan.net/sec-filings/XNCR/form-4-xencor-inc-insider-trading-activity-a04912138dc6.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:35:30", "published_display": "08 Jul 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $27", "summary": "Truist Financial has reiterated its Buy rating on Xencor (XNCR.US) shares, despite lowering its target price to $27. This decision likely reflects a continued positive outlook on the company's long-term prospects while adjusting for recent financial or market developments.", "url": "https://www.moomoo.com/news/post/72590454/truist-financial-maintains-xencor-xncrus-with-buy-rating-cuts-target", "source_name": "Moomoo", "published_at": "2026-07-07T22:35:30", "published_display": "07 Jul 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XENCOR Maintains Buy Rating -- Price Target Lowered to $27.00 by Truist Securities", "summary": "Truist Securities maintained a Buy rating for Xencor (XNCR) but lowered its price target from $29.00 to $27.00, reflecting cautious optimism. Despite the maintained rating, GuruFocus indicates that Xencor is significantly overvalued by 56.2%, trading at $14.89 against a GF Value\u2122", "url": "https://www.gurufocus.com/news/8947471/xencor-maintains-buy-rating-price-target-lowered-to-2700-by-truist-securities", "source_name": "GuruFocus", "published_at": "2026-07-07T13:40:42", "published_display": "07 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XNCR - Xencor Inc Revenue Breakdown", "summary": "This article provides a financial breakdown of Xencor Inc (XNCR), detailing key financial metrics such as market capitalization, revenue, income, sales, and various ratios. It includes per-share data, growth rates, insider and institutional ownership, and stock performance over d", "url": "https://finviz.com/stock?t=XNCR&ta=1&p=d&ty=rv&r=m6", "source_name": "Finviz", "published_at": "2026-07-06T10:12:15", "published_display": "06 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Xencor, Inc. \u2013 NASDAQ:XNCR", "summary": "This article provides financial information for Xencor, Inc. (NASDAQ: XNCR) on TradingView, specifically focusing on its Price to Sales (forward) metric. It lists the period, value, and percentage change for this financial indicator, indicating that the data is generated by human", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T11:10:40", "published_display": "02 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Xencor, Inc. \u2013 NASDAQ:XNCR", "summary": "This page provides information on the forward price-to-earnings ratio for Xencor, Inc. (NASDAQ: XNCR). It is a financial data point presented within the context of TradingView's platform, offering financial information for various market instruments. The content is primarily navi", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T08:40:26", "published_display": "02 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Xencor, Inc. \u2013 TRADEGATE:XE9", "summary": "This article provides financial information for Xencor, Inc. (TRADEGATE:XE9), specifically focusing on its price-to-sales forward metric. It details that while the market is currently closed with no trades, financial data and analysis are available, supplied by various financial ", "url": "https://www.tradingview.com/symbols/TRADEGATE-XE9/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T08:10:37", "published_display": "02 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Xencor, Inc. \u2013 NASDAQ:XNCR", "summary": "This article provides a financial snapshot for Xencor, Inc. (NASDAQ: XNCR) focusing on its enterprise value to revenue. It indicates that the content is primarily data-driven, likely showing financial metrics for the company. The main source appears to be TradingView, offering an", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T00:10:37", "published_display": "02 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (XNCR) Price Events", "summary": "Xencor Inc. (NASDAQ: XNCR) shows strong sentiment across all horizons, supporting an overweight bias according to AI models. The analysis identifies a mid-channel oscillation pattern and offers an exceptional 65.6:1 risk-reward short setup. Three distinct institutional trading st", "url": "https://news.stocktradersdaily.com/news_release/23/Liquidity_Mapping_Around_XNCR_Price_Events_062926101201_1782785521.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T22:12:00", "published_display": "29 Jun 2026 22:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XE9 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Xencor, Inc. (XE9) stock, based on analyst opinions. It includes future price estimates, details on past earnings and revenue, and key financial metrics like EBITDA. The article also covers frequently asked questions about XE9", "url": "https://www.tradingview.com/symbols/BX-XE9/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T20:40:12", "published_display": "27 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor, Inc. Actuals & Estimates (FWB:XE9)", "summary": "This article provides an overview of Xencor, Inc. (FWB:XE9) financial actuals and estimates, including its stock ticker, forecast, historical prices, and dividend policy. It details the company's past earnings and revenue figures, as well as estimates for upcoming quarters, and n", "url": "https://www.tradingview.com/symbols/FWB-XE9/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T18:41:09", "published_display": "26 Jun 2026 18:41", "sentiment": "negative", "sentiment_pct": 20, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XNCR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Xencor, Inc. (XNCR) stock, including analyst price targets, current stock performance, and key financial data. It highlights that analysts have a maximum price estimate of $43.00 and a minimum of $14.00, with the stock recently increasing by 2", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:49", "published_display": "25 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor, Inc. Actuals & Estimates (NASDAQ:XNCR)", "summary": "This article provides key financial data and analyst estimates for Xencor, Inc. (NASDAQ: XNCR), including its current stock price, historical performance, analyst price targets, and upcoming earnings report. It covers various financial metrics such as revenue, net income, and mar", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:48", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Xencor, Inc. \u2013 NASDAQ:XNCR", "summary": "This article displays the \"Price to book forward\" financial metric for Xencor, Inc. (NASDAQ: XNCR) as presented on TradingView. It provides a snapshot of this specific financial data point for the biotechnology company. The content appears to be a stub or a data-focused page from", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T09:10:38", "published_display": "25 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor director Ellen Feigal sells $89,369 in company stock By Investing.com", "summary": "Xencor director Ellen Feigal sold 6,843 shares of the company's common stock for $89,369 on June 18, 2026, through a pre-arranged trading plan. Following the sale, Ms. Feigal directly holds 12,340 shares. This transaction occurs as Xencor shares have gained 48% over the past year", "url": "https://ng.investing.com/news/stock-market-news/xencor-director-ellen-feigal-sells-89369-in-company-stock-93CH-2568507", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T05:09:58", "published_display": "23 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Ellen Feigal Sells Shares of Xencor Inc (XNC", "summary": "Ellen Feigal, a Director at Xencor Inc (XNCR), sold 6,843 shares of the company on June 18, 2026. This transaction follows a pattern of 15 insider sells and no buys at Xencor over the past year. With shares trading at $13.06 and a GF Value of $9.62, the stock is considered signif", "url": "https://www.gurufocus.com/news/8925865/insider-sell-alert-ellen-feigal-sells-shares-of-xencor-inc-xncr", "source_name": "GuruFocus", "published_at": "2026-06-23T04:40:00", "published_display": "23 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) director\u2019s 10b5-1 sale covers 6,843 common shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQllFWjdBa1JsTGowcWJjTjUxRzY2SUpaVGxpUXc5dGNHZnpPMm1LQ2tuYUJVV2d3akg3STJLQzJzVXBvbmxVUEZmM281ekh5UkExSUplbGtIcW1wUzdad1h6LUI2NGxhQ19ONDBnWlY3Mlh0MjhZSzBaMjI0NHd3NDVBRzRFYW5RYndURkhqdE5ITDNWVktjZGFHZUR5X1JRQjRwT3AxZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor, Inc. Files 8-K: Company Details, Stock Info, and Executive Plan Updates for 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPYTBfTkFYVGxoSmstVmFSajQ4c3pfaVRyekdSU1g3VkswQnRPenFDVzVudlU0amM0YVJQbmJpQ3ByMXR2VjdBa0p3OUp3NXpmX0xUZUdqRlBzczJNNGU3Q0JXTS1IbzRTMXBlQW9vTlJMRll5cmcxX2RKNHgybW1tOXFpVnl0UDJGTDFCbG5zcnFMMUgwcXV5c2Q0NHIxWUc0Y2RTQUtrQTNXSFBUT05GVjlDRHl4UzVrVUJpN3hnNkNXdw?oc=5", "source_name": "Minichart", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Xencor Inc SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNWERWck1MNHV5T1lERkVXVU9rcFUxS3o3eWJjb1l5R012TE9lLXhjdGoyUDhRdXBwX1Jhb1VNQzJReGVacWR1b3VXR1FyV0lzSWc0S2tLTHFJZTZxUk1jN2hESGRpY3pXWTNtQXhTUFdfWUlXQ0ZtaXJnWDVSQ3FDWXJETV9IeWdRMlNNSWhoaWw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (NASDAQ: XNCR) investors back 4M-share equity plan boost and all proposals", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPcHlUbFFpNHdJZ3JuYjF0cGs4VlN6MWNhazdSQzFLVHpaTTVnalBEZGRIOWdWV25iTlgtT0xESzBKaGI1MF9tUi1ybVhfZjk3RzF4MWxpdGhJNjdMNnBIbkl1UGlZa3JlWS1icmdOcVZVQ2FtU2I0WGlKTWpMX2s0enpoQ1lnazUtMnRXR3VKUWJfcjBza0RGeGFjUzdGZW9Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) director sells 5,474 shares under Rule 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxObzBCelFpMlVXUUZkQlh0SUF3YlFMZVB1TlRmR0x5eFpVbWVLZWlPR0Vibkx1Um9mbFF2dHdLcllEczhtSlFxUC10NW13VVJ5SFdjZnZKZkhaU2hQY0NIdmY0Qy1oTy14Q2pqTG9pRW5mM1QtX1hJbzIwZk9XY1lQMzAwMk1iV1BSTktFRjNKV0h0S3h5NG9CcGx6d2wxLXNvNHpGWVpfUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Xencor (XNCR) sells 7,527 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOWHdZbHpsN0pROW9ocHBvU003WnpGRzNxcXFJa0RLdTNFUWdIaHVmU1ZjWlRxUEM4clF2Yi1zM280clNSbzJRMklRYzdCLVZZclNuTFVWVm5weWQ3bmVpdEpOSmpfc1VBS0pCTWQ3dTJUM2VhcUY3RnhfaGI2SjRHQm1Kdzk4cVVPSThQUDBIN094U2JOc1lRV21pT0lDSmk3TWFnal9Nbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/xencor-xncr-stock-draws-fresh-051132610.html", "source_name": "Simply Wall St.", "published_at": "2026-06-14T05:11:32+00:00", "published_display": "14 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor Inc stock (US98401F1057): shares react to Monjuvi first-line lymphoma update and recent Q1 20", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOSGp4WTIybU1vUm1aVHNYNFpKekMyTTRObDhlbm9seHJ4ZG4taVdtTnNWNEFHaUl1cDBVS0wyZWtGaWEteGpJNEhZSDUwdmhTdDlWTGVzbnJBOVA1SnIwNFJNR051Y0txNlJsXzdNVmdKcFJGZFk5aENJeER4UndHZlZ6MlZjTXFYb0tvbFV0U0JhQ2w2RUdNVjZJZUtiYmVDZExSck9iZnhrOERUS3B6TFkyaGd3Q0FpR0lBX0RWSUo?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XNCR - Xencor Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE9tcWN3eV9MSVNMRkJOSXBNaWdpOU95TGNCYWhSN0ZpSGJiNS1BYzV3MHFkNzlSWW1DOUljM0JCY0NrRnFTX0E?oc=5", "source_name": "Finviz", "published_at": "2026-05-28T07:57:14+00:00", "published_display": "28 May 2026 07:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/bi-multispecific-drugs-oncology-analytical-092200845.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T09:22:00+00:00", "published_display": "12 May 2026 09:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/analysts-think-xencor-inc-nasdaq-111142363.html", "source_name": "Simply Wall St.", "published_at": "2026-05-08T11:11:42+00:00", "published_display": "08 May 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xencor-q1-earnings-snapshot-200850424.html", "source_name": "Associated Press", "published_at": "2026-05-06T20:08:50+00:00", "published_display": "06 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026", "summary": "", "url": "https://finance.yahoo.com/m/216948e1-3d30-3a26-847e-82df30890428/xencor-highlights-xmab942.html", "source_name": "MarketBeat", "published_at": "2026-05-06T10:12:07+00:00", "published_display": "06 May 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQaFZLTm1YZlZBREgzZExndUlTTWJGRW16Y1dPbjB3RWl5SVFfNl9Icnp3eG9JMmF5MUtydF85OTJXTmp1aktrQ1lNRUNpNHNnRlFISXJ6WkF6akhWTmFhbG5weVNwMjRvMi14SEZJRVFYeDE3UzAyNmdVM1k0YUpteEVOYmMtZXV4RXpOS2h0a0pzUk9PZkk5dGoxalZmUkdqYTMtLXk0UWV3NXN5?oc=5", "source_name": "Business Wire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxORUU2MGd3M3VkcC1CczQzNUNSUnNKUjYwZFBxZF9zZWFOY0FfTEFYMDBMbFVKRnVUYnduR3Nnb1ZzQ1JZLU5BTDl2LXpZYjB5Y3VaaklCb21KOVpQOEl0c3lTLWRGOWtyOWljc2RsbXpBUkpLTXlES2ktTnBOeVZiTzRKOVhiZmZETmhfcFRwYlA0a2VWU1BkT1hTRjQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPZ0stbVgtMGxmZ21HaERlZWo2WnRjaElicm02dUZ3M19hbEtvTzFrem13LTQ4VU42YXFlZFNNbFI1clZ5Q1Z0NXJLaklqVFhKTjhQa3FhNlNwemEyV2lMamloUmhsb09TMXp6bXlRQ2I3Z0hJbW0yN1lObFNMTjBMdlg4NER5V1VTdjl1NjZzU3JDaGJLRVFFdFZYTTNsNU0wNWJwdy1aSnFTWTlIS240dVNPUlVmY25sSzdPVnZadHNjR3RaemsyUGUtVmdkTmZSVVE?oc=5", "source_name": "Business Wire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xencor stock downgraded to neutral at JPMorgan on execution concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNbkw3elg0cjJVUFJJakF3MEIzSzlNUnRFV0swS3pWc0F6OVlLSTFYV0YyNTNqcXNjRVRxZ283T0tldmJ0WmJ4UEJneTBMWGRBYmVOaHVXU3I1VG0tOThra2JFMWJTanM5MXhRVm05SWVyWXpLZmJXeHo0andHM291UmZDczVCaGdqX2hOVXZ4YjJNQzZFSWVMSW9LaVZfcUlsc1R6ZVhzVTQxcF9vVVJfNjBHQnZHNWQxeW9TSWJvS2FUNEpWdU1R?oc=5", "source_name": "Investing.com", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPcDVybjY3UkFWZFBhRExLTUk4RE9zc0tUUk5QNE9jbEw5R09tcnVRTHc2SkUtSERpTG5rX3VDak53Tl9HWTRaY2dnRWQ3T1VJWDNjeWtRQmdSV19ZQmV2YXQ1Z1BKNHBrNjJMcWtnX00zNlEwVHh6dEU5Tk55ZjNKZ29raXRKYmVNT013?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Xencor (XNCR)'s 2026 XmAb Pivotal Plans and Cash Runway Through 2028 Mean For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Xencor (XNCR) Now Fairly Priced After Prolonged Share Price Declines", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus", "summary": "This article analyzes two Federal Circuit decisions, *Teva v. Eli Lilly* and *In re Xencor*, which provide guidance on patent method-of-use claims involving known compounds. The decisions highlight the importance of written description and enablement under 35 U.S.C. \u00a7 112, partic", "url": "https://www.foley.com/insights/publications/2026/07/pharmaceutical-method-of-use-claims-after-teva-v-eli-lilly-and-in-re-xencor-written-description-enablement-and-the-known-compound-genus/", "source_name": "Foley & Lardner LLP", "published_at": "2026-07-15T17:48:28", "published_display": "15 Jul 2026 17:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor: Bullish On Their Increasingly In-House Pipeline (NASDAQ:XNCR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQTk5HdHhXOTVzQzdqQ2Q2VzdSLWhKMDUtSlV4MUVuNEFDUWZEcFlsUzh4WmE0ZHZQZzBLT2k2LVdlc3pHQ1V0TWJuN1hSRzdyc3NUTmhuTVo3VzNoVC1xVE51MHYzTzRSTEloYmFxM0UxcXljX2NjaVplTTFRQ2wya1J6UnFqQmdqemVLbEFEZTNPd1VDal9mMEMtQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T20:01:56+00:00", "published_display": "14 Jul 2026 20:01", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (NASDAQ:XNCR) Shares Down 6.6% - Should You Sell?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNTVltdGJ0SV90U0pybHlteU5kRTA5OTJrR0ZxVlhtY2ZqVUN4RFFvQnloMU4yZlVFS05FUGJLdWp1M3lma1Z0aWFCNWN6QVRDTDFIaU9aVTlGWmVsaFRLUk8tNTdERUpab2M1Z195VkdwRFl3S0wwNGNKWlJzSUJsYUwxYkNhYjd6dU5LVm5ScjdwU1ZBREl4M0lBWUxyM3k4SVByRg?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-13T18:19:19+00:00", "published_display": "13 Jul 2026 18:19", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of \"Moderate Buy\" from Analysts", "summary": "Xencor, Inc. (NASDAQ:XNCR) has received a consensus \"Moderate Buy\" rating from analysts, with ten firms covering the stock and an average 1-year price target of $24.25. Recent analyst actions have been mixed, including Truist lowering its target but maintaining a buy rating, and ", "url": "https://www.marketbeat.com/instant-alerts/xencor-inc-nasdaqxncr-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T07:11:54", "published_display": "13 Jul 2026 07:11", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) Rebounds Sharply, Is It Still A Bargain?", "summary": "Xencor (XNCR) has seen a sharp rebound in its share price recently, with 30-day and 90-day returns of 33.98% and 27.62% respectively, despite a longer-term decline. Analysts consider Xencor undervalued with a fair value of $28.50 compared to its current $15.85, driven by its modu", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xncr/xencor/news/xencor-xncr-rebounds-sharply-is-it-still-a-bargain", "source_name": "Simply Wall Street", "published_at": "2026-07-12T00:41:29", "published_display": "12 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(XNCR) Movement as an Input in Quant Signal Sets", "summary": "This article provides an in-depth quantitative analysis of Xencor Inc. (NASDAQ: XNCR) based on AI models from Stock Traders Daily. It highlights strong sentiment across all horizons, identifies a mid-channel oscillation pattern, and outlines specific trading strategies (Position,", "url": "https://news.stocktradersdaily.com/news_release/1/XNCR_Movement_as_an_Input_in_Quant_Signal_Sets_071026112002_1783740002.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T23:20:00", "published_display": "10 Jul 2026 23:20", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Xencor Inc For: 8 July By Investing.com", "summary": "This article from Investing.com reports the filing of a Form 4 for Xencor Inc, dated July 8th. The brief news item also mentions Xencor's stock, XNCR, experiencing a -2.13% change. The content primarily focuses on market data, unrelated news headlines, and advertising rather than", "url": "https://ng.investing.com/news/stock-market-news/form-4-xencor-inc-for-8-july-93CH-2592039", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T10:41:18", "published_display": "09 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) director granted RSUs and 20,604 stock options at $12.20", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNS0lRcGFSZkF4b3NUT19ueGJCbk1Oci1TbE5SdWlhY19HelJac1MyQXdJeXhyU0JwNGdkeEE1eGxac0d4dlBSQlhwalBtSkp2SGM3WXVwNFpWVmJiX0FSYm5RbDhNcUdJY3ZYZUQ1RDBlNFphbWlvNl8tLXFZSUkwZnQzbWR6bm4xLXdJVzRGdTdrNVlRYTRsRDhLYTZxMXRiSkczSUxFMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T22:53:49+00:00", "published_display": "08 Jul 2026 22:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (NASDAQ: XNCR) director receives new RSU and stock option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOd0FDZVA3Z1VSNXdjQ2ZPLW9icjE3SkRTajhXODZYWGJUMk44UEs1ZVI1SW04R1dseVM2VHFvcUV1T2FWT2o4SGR2Y3ZIemNENUFsOWc3Qm95V1RidFV1b1E5TmRneGM4d2hOOVdvRDU1RXNtR1d0YTJmQ3BqY21rUWZXN0NUVW10ekJCMG1DVm1UOExzSVhfbElYdmtVYjBMLUViYkhvYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T22:52:20+00:00", "published_display": "08 Jul 2026 22:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) director granted RSUs and stock options in equity award", "summary": "Xencor Inc. director Alan Bruce Montgomery received equity compensation, not open-market stock purchases, consisting of 10,302 restricted stock units (RSUs) and options for 20,604 shares. The RSUs will vest fully on the first anniversary of the grant date, while the stock options", "url": "https://www.stocktitan.net/sec-filings/XNCR/form-4-xencor-inc-insider-trading-activity-38aa42b7ba3a.html", "source_name": "Stock Titan", "published_at": "2026-07-08T23:10:40", "published_display": "08 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) director Kurt Gustafson granted RSUs and stock options", "summary": "Xencor director Kurt A. Gustafson received 10,302 restricted stock units (RSUs) and options for 20,604 shares of Common Stock with an exercise price of $12.20. These equity awards, not open-market trades, are part of his compensation, with RSUs vesting on the first anniversary of", "url": "https://www.stocktitan.net/sec-filings/XNCR/form-4-xencor-inc-insider-trading-activity-1f92ecef9d95.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:55:27", "published_display": "08 Jul 2026 22:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Xencor Inc Insider Trading Activity", "summary": "Xencor Inc. director Barbara Klencke recently reported receiving equity compensation. This included 10,302 restricted stock units vesting a year from June 16, 2026, and options to purchase 20,604 shares at an exercise price of $12.20, vesting monthly over one year. Following thes", "url": "https://www.stocktitan.net/sec-filings/XNCR/form-4-xencor-inc-insider-trading-activity-8fb0259010bc.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:54:27", "published_display": "08 Jul 2026 22:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ellen Feigal at Xencor (XNCR) receives RSUs and options equity awards", "summary": "Xencor Inc. director Ellen Feigal was granted 10,302 restricted stock units (RSUs) and stock options for 20,604 shares. The RSUs will fully vest on June 16, 2027, one year from the grant date, while the stock options, with an exercise price of $12.20 per share, will vest in equal", "url": "https://www.stocktitan.net/sec-filings/XNCR/form-4-xencor-inc-insider-trading-activity-da620bd99669.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:35:30", "published_display": "08 Jul 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) awards RSUs and stock options to director Gorman", "summary": "Xencor Inc. (XNCR) director Kevin Charles Gorman was granted 10,302 restricted stock units (RSUs) and stock options for 20,604 shares on June 16, 2026, as part of his compensation. The RSUs will vest fully on the first anniversary of the grant date, while the stock options, with ", "url": "https://www.stocktitan.net/sec-filings/XNCR/form-4-xencor-inc-insider-trading-activity-a04912138dc6.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:35:30", "published_display": "08 Jul 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $27", "summary": "Truist Financial has reiterated its Buy rating on Xencor (XNCR.US) shares, despite lowering its target price to $27. This decision likely reflects a continued positive outlook on the company's long-term prospects while adjusting for recent financial or market developments.", "url": "https://www.moomoo.com/news/post/72590454/truist-financial-maintains-xencor-xncrus-with-buy-rating-cuts-target", "source_name": "Moomoo", "published_at": "2026-07-07T22:35:30", "published_display": "07 Jul 2026 22:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XENCOR Maintains Buy Rating -- Price Target Lowered to $27.00 by Truist Securities", "summary": "Truist Securities maintained a Buy rating for Xencor (XNCR) but lowered its price target from $29.00 to $27.00, reflecting cautious optimism. Despite the maintained rating, GuruFocus indicates that Xencor is significantly overvalued by 56.2%, trading at $14.89 against a GF Value\u2122", "url": "https://www.gurufocus.com/news/8947471/xencor-maintains-buy-rating-price-target-lowered-to-2700-by-truist-securities", "source_name": "GuruFocus", "published_at": "2026-07-07T13:40:42", "published_display": "07 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XNCR - Xencor Inc Revenue Breakdown", "summary": "This article provides a financial breakdown of Xencor Inc (XNCR), detailing key financial metrics such as market capitalization, revenue, income, sales, and various ratios. It includes per-share data, growth rates, insider and institutional ownership, and stock performance over d", "url": "https://finviz.com/stock?t=XNCR&ta=1&p=d&ty=rv&r=m6", "source_name": "Finviz", "published_at": "2026-07-06T10:12:15", "published_display": "06 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Xencor, Inc. \u2013 NASDAQ:XNCR", "summary": "This article provides financial information for Xencor, Inc. (NASDAQ: XNCR) on TradingView, specifically focusing on its Price to Sales (forward) metric. It lists the period, value, and percentage change for this financial indicator, indicating that the data is generated by human", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T11:10:40", "published_display": "02 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Xencor, Inc. \u2013 NASDAQ:XNCR", "summary": "This page provides information on the forward price-to-earnings ratio for Xencor, Inc. (NASDAQ: XNCR). It is a financial data point presented within the context of TradingView's platform, offering financial information for various market instruments. The content is primarily navi", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T08:40:26", "published_display": "02 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Xencor, Inc. \u2013 TRADEGATE:XE9", "summary": "This article provides financial information for Xencor, Inc. (TRADEGATE:XE9), specifically focusing on its price-to-sales forward metric. It details that while the market is currently closed with no trades, financial data and analysis are available, supplied by various financial ", "url": "https://www.tradingview.com/symbols/TRADEGATE-XE9/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T08:10:37", "published_display": "02 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Xencor, Inc. \u2013 NASDAQ:XNCR", "summary": "This article provides a financial snapshot for Xencor, Inc. (NASDAQ: XNCR) focusing on its enterprise value to revenue. It indicates that the content is primarily data-driven, likely showing financial metrics for the company. The main source appears to be TradingView, offering an", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T00:10:37", "published_display": "02 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (XNCR) Price Events", "summary": "Xencor Inc. (NASDAQ: XNCR) shows strong sentiment across all horizons, supporting an overweight bias according to AI models. The analysis identifies a mid-channel oscillation pattern and offers an exceptional 65.6:1 risk-reward short setup. Three distinct institutional trading st", "url": "https://news.stocktradersdaily.com/news_release/23/Liquidity_Mapping_Around_XNCR_Price_Events_062926101201_1782785521.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-29T22:12:00", "published_display": "29 Jun 2026 22:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XE9 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Xencor, Inc. (XE9) stock, based on analyst opinions. It includes future price estimates, details on past earnings and revenue, and key financial metrics like EBITDA. The article also covers frequently asked questions about XE9", "url": "https://www.tradingview.com/symbols/BX-XE9/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T20:40:12", "published_display": "27 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor, Inc. Actuals & Estimates (FWB:XE9)", "summary": "This article provides an overview of Xencor, Inc. (FWB:XE9) financial actuals and estimates, including its stock ticker, forecast, historical prices, and dividend policy. It details the company's past earnings and revenue figures, as well as estimates for upcoming quarters, and n", "url": "https://www.tradingview.com/symbols/FWB-XE9/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T18:41:09", "published_display": "26 Jun 2026 18:41", "sentiment": "negative", "sentiment_pct": 20, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XNCR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Xencor, Inc. (XNCR) stock, including analyst price targets, current stock performance, and key financial data. It highlights that analysts have a maximum price estimate of $43.00 and a minimum of $14.00, with the stock recently increasing by 2", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:49", "published_display": "25 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor, Inc. Actuals & Estimates (NASDAQ:XNCR)", "summary": "This article provides key financial data and analyst estimates for Xencor, Inc. (NASDAQ: XNCR), including its current stock price, historical performance, analyst price targets, and upcoming earnings report. It covers various financial metrics such as revenue, net income, and mar", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T19:11:48", "published_display": "25 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Xencor, Inc. \u2013 NASDAQ:XNCR", "summary": "This article displays the \"Price to book forward\" financial metric for Xencor, Inc. (NASDAQ: XNCR) as presented on TradingView. It provides a snapshot of this specific financial data point for the biotechnology company. The content appears to be a stub or a data-focused page from", "url": "https://www.tradingview.com/symbols/NASDAQ-XNCR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T09:10:38", "published_display": "25 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor director Ellen Feigal sells $89,369 in company stock By Investing.com", "summary": "Xencor director Ellen Feigal sold 6,843 shares of the company's common stock for $89,369 on June 18, 2026, through a pre-arranged trading plan. Following the sale, Ms. Feigal directly holds 12,340 shares. This transaction occurs as Xencor shares have gained 48% over the past year", "url": "https://ng.investing.com/news/stock-market-news/xencor-director-ellen-feigal-sells-89369-in-company-stock-93CH-2568507", "source_name": "Investing.com Nigeria", "published_at": "2026-06-23T05:09:58", "published_display": "23 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Ellen Feigal Sells Shares of Xencor Inc (XNC", "summary": "Ellen Feigal, a Director at Xencor Inc (XNCR), sold 6,843 shares of the company on June 18, 2026. This transaction follows a pattern of 15 insider sells and no buys at Xencor over the past year. With shares trading at $13.06 and a GF Value of $9.62, the stock is considered signif", "url": "https://www.gurufocus.com/news/8925865/insider-sell-alert-ellen-feigal-sells-shares-of-xencor-inc-xncr", "source_name": "GuruFocus", "published_at": "2026-06-23T04:40:00", "published_display": "23 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) director\u2019s 10b5-1 sale covers 6,843 common shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPQllFWjdBa1JsTGowcWJjTjUxRzY2SUpaVGxpUXc5dGNHZnpPMm1LQ2tuYUJVV2d3akg3STJLQzJzVXBvbmxVUEZmM281ekh5UkExSUplbGtIcW1wUzdad1h6LUI2NGxhQ19ONDBnWlY3Mlh0MjhZSzBaMjI0NHd3NDVBRzRFYW5RYndURkhqdE5ITDNWVktjZGFHZUR5X1JRQjRwT3AxZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor, Inc. Files 8-K: Company Details, Stock Info, and Executive Plan Updates for 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPYTBfTkFYVGxoSmstVmFSajQ4c3pfaVRyekdSU1g3VkswQnRPenFDVzVudlU0amM0YVJQbmJpQ3ByMXR2VjdBa0p3OUp3NXpmX0xUZUdqRlBzczJNNGU3Q0JXTS1IbzRTMXBlQW9vTlJMRll5cmcxX2RKNHgybW1tOXFpVnl0UDJGTDFCbG5zcnFMMUgwcXV5c2Q0NHIxWUc0Y2RTQUtrQTNXSFBUT05GVjlDRHl4UzVrVUJpN3hnNkNXdw?oc=5", "source_name": "Minichart", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Xencor Inc SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNWERWck1MNHV5T1lERkVXVU9rcFUxS3o3eWJjb1l5R012TE9lLXhjdGoyUDhRdXBwX1Jhb1VNQzJReGVacWR1b3VXR1FyV0lzSWc0S2tLTHFJZTZxUk1jN2hESGRpY3pXWTNtQXhTUFdfWUlXQ0ZtaXJnWDVSQ3FDWXJETV9IeWdRMlNNSWhoaWw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (NASDAQ: XNCR) investors back 4M-share equity plan boost and all proposals", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPcHlUbFFpNHdJZ3JuYjF0cGs4VlN6MWNhazdSQzFLVHpaTTVnalBEZGRIOWdWV25iTlgtT0xESzBKaGI1MF9tUi1ybVhfZjk3RzF4MWxpdGhJNjdMNnBIbkl1UGlZa3JlWS1icmdOcVZVQ2FtU2I0WGlKTWpMX2s0enpoQ1lnazUtMnRXR3VKUWJfcjBza0RGeGFjUzdGZW9Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) director sells 5,474 shares under Rule 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxObzBCelFpMlVXUUZkQlh0SUF3YlFMZVB1TlRmR0x5eFpVbWVLZWlPR0Vibkx1Um9mbFF2dHdLcllEczhtSlFxUC10NW13VVJ5SFdjZnZKZkhaU2hQY0NIdmY0Qy1oTy14Q2pqTG9pRW5mM1QtX1hJbzIwZk9XY1lQMzAwMk1iV1BSTktFRjNKV0h0S3h5NG9CcGx6d2wxLXNvNHpGWVpfUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Xencor (XNCR) sells 7,527 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOWHdZbHpsN0pROW9ocHBvU003WnpGRzNxcXFJa0RLdTNFUWdIaHVmU1ZjWlRxUEM4clF2Yi1zM280clNSbzJRMklRYzdCLVZZclNuTFVWVm5weWQ3bmVpdEpOSmpfc1VBS0pCTWQ3dTJUM2VhcUY3RnhfaGI2SjRHQm1Kdzk4cVVPSThQUDBIN094U2JOc1lRV21pT0lDSmk3TWFnal9Nbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/xencor-xncr-stock-draws-fresh-051132610.html", "source_name": "Simply Wall St.", "published_at": "2026-06-14T05:11:32+00:00", "published_display": "14 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor Inc stock (US98401F1057): shares react to Monjuvi first-line lymphoma update and recent Q1 20", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOSGp4WTIybU1vUm1aVHNYNFpKekMyTTRObDhlbm9seHJ4ZG4taVdtTnNWNEFHaUl1cDBVS0wyZWtGaWEteGpJNEhZSDUwdmhTdDlWTGVzbnJBOVA1SnIwNFJNR051Y0txNlJsXzdNVmdKcFJGZFk5aENJeER4UndHZlZ6MlZjTXFYb0tvbFV0U0JhQ2w2RUdNVjZJZUtiYmVDZExSck9iZnhrOERUS3B6TFkyaGd3Q0FpR0lBX0RWSUo?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XNCR - Xencor Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE9tcWN3eV9MSVNMRkJOSXBNaWdpOU95TGNCYWhSN0ZpSGJiNS1BYzV3MHFkNzlSWW1DOUljM0JCY0NrRnFTX0E?oc=5", "source_name": "Finviz", "published_at": "2026-05-28T07:57:14+00:00", "published_display": "28 May 2026 07:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/bi-multispecific-drugs-oncology-analytical-092200845.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T09:22:00+00:00", "published_display": "12 May 2026 09:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/analysts-think-xencor-inc-nasdaq-111142363.html", "source_name": "Simply Wall St.", "published_at": "2026-05-08T11:11:42+00:00", "published_display": "08 May 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xencor-q1-earnings-snapshot-200850424.html", "source_name": "Associated Press", "published_at": "2026-05-06T20:08:50+00:00", "published_display": "06 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026", "summary": "", "url": "https://finance.yahoo.com/m/216948e1-3d30-3a26-847e-82df30890428/xencor-highlights-xmab942.html", "source_name": "MarketBeat", "published_at": "2026-05-06T10:12:07+00:00", "published_display": "06 May 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQaFZLTm1YZlZBREgzZExndUlTTWJGRW16Y1dPbjB3RWl5SVFfNl9Icnp3eG9JMmF5MUtydF85OTJXTmp1aktrQ1lNRUNpNHNnRlFISXJ6WkF6akhWTmFhbG5weVNwMjRvMi14SEZJRVFYeDE3UzAyNmdVM1k0YUpteEVOYmMtZXV4RXpOS2h0a0pzUk9PZkk5dGoxalZmUkdqYTMtLXk0UWV3NXN5?oc=5", "source_name": "Business Wire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxORUU2MGd3M3VkcC1CczQzNUNSUnNKUjYwZFBxZF9zZWFOY0FfTEFYMDBMbFVKRnVUYnduR3Nnb1ZzQ1JZLU5BTDl2LXpZYjB5Y3VaaklCb21KOVpQOEl0c3lTLWRGOWtyOWljc2RsbXpBUkpLTXlES2ktTnBOeVZiTzRKOVhiZmZETmhfcFRwYlA0a2VWU1BkT1hTRjQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPZ0stbVgtMGxmZ21HaERlZWo2WnRjaElicm02dUZ3M19hbEtvTzFrem13LTQ4VU42YXFlZFNNbFI1clZ5Q1Z0NXJLaklqVFhKTjhQa3FhNlNwemEyV2lMamloUmhsb09TMXp6bXlRQ2I3Z0hJbW0yN1lObFNMTjBMdlg4NER5V1VTdjl1NjZzU3JDaGJLRVFFdFZYTTNsNU0wNWJwdy1aSnFTWTlIS240dVNPUlVmY25sSzdPVnZadHNjR3RaemsyUGUtVmdkTmZSVVE?oc=5", "source_name": "Business Wire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xencor stock downgraded to neutral at JPMorgan on execution concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNbkw3elg0cjJVUFJJakF3MEIzSzlNUnRFV0swS3pWc0F6OVlLSTFYV0YyNTNqcXNjRVRxZ283T0tldmJ0WmJ4UEJneTBMWGRBYmVOaHVXU3I1VG0tOThra2JFMWJTanM5MXhRVm05SWVyWXpLZmJXeHo0andHM291UmZDczVCaGdqX2hOVXZ4YjJNQzZFSWVMSW9LaVZfcUlsc1R6ZVhzVTQxcF9vVVJfNjBHQnZHNWQxeW9TSWJvS2FUNEpWdU1R?oc=5", "source_name": "Investing.com", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPcDVybjY3UkFWZFBhRExLTUk4RE9zc0tUUk5QNE9jbEw5R09tcnVRTHc2SkUtSERpTG5rX3VDak53Tl9HWTRaY2dnRWQ3T1VJWDNjeWtRQmdSV19ZQmV2YXQ1Z1BKNHBrNjJMcWtnX00zNlEwVHh6dEU5Tk55ZjNKZ29raXRKYmVNT013?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Xencor (XNCR)'s 2026 XmAb Pivotal Plans and Cash Runway Through 2028 Mean For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-13T08:00:00+00:00", "published_display": "13 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Xencor (XNCR) Now Fairly Priced After Prolonged Share Price Declines", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 58, "sentiment_summary": {"positive": 5, "negative": 9, "neutral": 44, "score": 49, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 17.95, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 9.15, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 15.85, "latest_week": "2026-07-10", "one_week_move": 5.7, "four_week_move": 28.5, "twelve_week_move": 21.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.283692, "market_dynamics_buy_signal": false, "relative_strength": 9.912014, "fair_value_gap": -4.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.6124, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.7% over one week, +28.5% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "TradingView", "count": 10}, {"label": "Market source", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "MarketBeat", "count": 3}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "GuruFocus", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "49/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.7% over one week, +28.5% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus"}], "updated_at": "2026-07-16T11:51:23.753862+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}